Overcoming the Limitations of Conventional Cell Engineering episode artwork

EPISODE · Jul 8, 2021 · 30 MIN

Overcoming the Limitations of Conventional Cell Engineering

from RARECast

DNA-modified cells can behave unpredictably in the body and there is a risk that they could proliferate uncontrolled, cause severe toxicities, and even survive unchecked for months or years. Cartesian uses its platform technology to engineer RNA into cells, making time-controlled changes. The company is developing treatments for cancer, respiratory conditions, and autoimmune diseases such as myasthenia gravis. We spoke to Murat Kalayoglu, president and CEO of Cartesian, about its RNA-engineered cell therapies, how they work and how the company is pushing the use of cell therapies beyond cancer. 

Episode metadata supplied by the publisher feed · Published Jul 8, 2021

Embed this episode

Murat Kalayoglu, president and CEO of Cartesian Therapeutics, discusses the company’s RNA-engineered cell therapies, how they work, and how the company is pushing the use of cell therapies beyond cancer.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Overcoming the Limitations of Conventional Cell Engineering

0:00 30:35

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of RARECast?

This episode is 30 minutes long.

When was this RARECast episode published?

This episode was published on July 8, 2021.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!